-$0.24 Earnings Per Share Expected for BioCardia, Inc. (NYSE:BCDA) This Quarter

Wall Street analysts forecast that BioCardia, Inc. (NYSE:BCDA) will announce ($0.24) earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for BioCardia’s earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.29). BioCardia reported earnings of ($0.55) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 56.4%. The firm is expected to announce its next quarterly earnings report on Tuesday, November 17th.

On average, analysts expect that BioCardia will report full year earnings of ($1.53) per share for the current fiscal year, with EPS estimates ranging from ($1.55) to ($1.50). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.75) per share, with EPS estimates ranging from ($1.09) to ($0.41). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow BioCardia.

BioCardia (NYSE:BCDA) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.21). The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.18 million.

Shares of BioCardia stock traded down $0.07 on Friday, hitting $2.30. The company’s stock had a trading volume of 19,080 shares, compared to its average volume of 101,542. BioCardia has a 52-week low of $2.01 and a 52-week high of $6.75. The firm has a fifty day moving average price of $2.32 and a 200-day moving average price of $2.97.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived from mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure.

Recommended Story: What is a management fee?

Get a free copy of the Zacks research report on BioCardia (BCDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.